An in-depth article in GenomeWeb highlights Sutter Health’s work with Canexia to assess if a “triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.” 

“While most organizations are still outsourcing NGS testing, health institutions are increasingly implementing local testing strategies. In a 2019 precision oncology survey of oncologists and pathologists conducted by Novartis, 83 percent said their organizations send out NGS testing to third-party labs. However, there was a 58 percent increase from 2018 to 2019 in respondents reporting they had in-house NGS testing. Faster turnaround time and better management of patients’ data were among the top advantages cited for in-house NGS testing.”

“An internal testing strategy can also help improve access to clinical trials, which are a big part of precision oncology programs but tend not to be broadly accessible within community practices where most patients get treated. With in-house testing, the institution maintains and manages patients’ samples, which also bolsters an institution’s ability to do research using patients’ biomarker data.” 

“For both Canexia and Sutter, there is also a health equity element to all this. Studies continue to show that despite greater availability of FDA-approved precision oncology treatments in recent years and exponential growth within the genetic testing industry, not all cancer patients are benefitting from these advances.”

Back

Recent Resources